Y-Mabs Therapeutics Inc. is a biotechnology company focused on discovering and developing innovative antibody therapeutics for the treatment of cancer, particularly in pediatric populations
The company specializes in engineered monoclonal antibodies designed to target specific tumor-associated antigens, leveraging advanced technologies to enhance therapeutic efficacy and safety. Y-Mabs is dedicated to addressing unmet medical needs by advancing its product candidates through clinical trials, with the goal of improving outcomes for patients with various forms of cancer.
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of stock of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB):
Shares of NetApp, Inc. (NASDAQ: NTAP) shares rose sharply in today’s pre-market trading after the company reported better-than-expected third-quarter financial results and issued guidance.
